An interventional study of Treatment with RefluxStop in GERD, sponsored by Implantica CE Reflux Ltd.. Status unknown at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-06.
Sponsored by Implantica CE Reflux Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Gastroesophageal Reflux with a site in Hungary — none open to participants now, none under way, none of them phase 3. Gastroesophageal Reflux · Hungary.
Among the 15 studies in Gastroesophageal Reflux with a site in Hungary, this one is the 15th largest by enrollment, is the only one that started in 2016, is the only one with no phase, and was the 14th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 15 studies in Gastroesophageal Reflux with a site in Hungary is open now. The open studies under Gastroesophageal Reflux, anywhere →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 628 across the 15 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 7 most frequent:
Implantica CE Reflux Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Implantica CE Reflux Ltd. has 4 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Gastroesophageal Reflux with a site in Hungary, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, open-label, multi-centre, single arm treatment only trial to evaluate the safety and effectiveness of RefluxStop for the treatment of GERD.
The used medical device "RefluxStop" is an implantable single use sterile device to ensure maintenance of gastro oesophageal junction (GEJ) in an intra-abdominal position to reduce or eliminate GERD.
The study plan will include a screening/baseline visit, a surgical procedure phase with hospital stay until discharge, and study visits at 6 weeks, 3 months and 6 months after device implantation.
A follow-up will be performed annually from years 1-5 to evaluate long-term safety and performance with the intention to collect post-market long-term data using the GERD-HRQL score as a screening tool. Data of subjects who agreed to participate in the long-term safety and performance will be analysed after 1, 2, 3, 4 and 5 years.
At the screening/baseline visit, after signing the informed consent, the eligibility of subjects to receive treatment with the study device will be determined. Eligible subjects will then undergo the device implant procedure.
A standard laparoscopic approach will be used to reposition the lower esophageal sphincter (LES) to its intra-abdominal position. The RefluxStop™ device will then be positioned and fixed in the gastric fundus to ensure intra-abdominal positioning of the GEJ at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed. The procedure will be recorded and saved only with study identification number and without subject ID information. The same applies for images on contrast swallow controlling the device.
Evaluations will be performed daily during hospitalisation and in an additional 3 study visits in the outpatient setting at 6 weeks, 3 months and 6 months. Subjects who have given their consent to participate in the long-term safety and performance follow-up part of the study will be followed annually from year 1-5.
A pathologically low pH in the lower esophagus is correlated to the development of precancerous changes/ Barrett's esophagus and fulminant cancer, as shown in the literature. Barrett's esophagus occurs in 1-2% of the total population while daily acid reflux patients have an incidence of 10-20% depending on the severity of the acid reflux [Modiano, Gerson 2007; Cossentino, Wong 2003]. As many as 48,000 people p.a. die in Europe and the US alone of esophageal adenocarcinoma, the primary cause of which is acid reflux. Therefore, in order to determine whether treatment is maintained in the longer-term, an additional 24-hour pH monitoring and simplified contrast swallow x-ray to verify the position of the device will be performed at 5 years for the benefit of the patients.
These long-term results have also been requested by the U.S. FDA. A quality control of the placement of the device will be categorized for subjects at after surgery, 6 months and 5 year follow-up and at therapy failure.
The position of the device is of utmost importance and will be categorized in the case of therapy failure.
To ensure a proper quality control, the contrast swallow x-ray determining eventual hiatal hernia performed before surgery is repeated at hospital stay after surgery and during the 6-month surgical outcome control and at 5-year follow-up. This x-ray is also used for categorizing the position of the device in a four-graded scale if therapy failure occurs and should be performed by the radiologist using the standard of care post-op contrast swallow.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled subjects will receive treatment for their GERD using the RefluxStop device intervention
Device: Treatment with RefluxStop
A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
Primary safety endpoint
Assessment of incidence of serious adverse device effects (SADEs) and procedure-related serious adverse events (SAEs)
Time frame: at 6 months
Primary efficacy endpoint
Percent reduction from baseline of GERD symptoms based on the GERD-HRQL score (questions 1-10). The data will also be presented as the number of subjects obtaining a 50% improvement of the baseline figures, with success defined as 60% of the subjects to reach such score improvement. Thus, the aim of this analysis is to show that the lower limit of the confidence interval exceeds 60%.
Time frame: at 6 months
Secondary safety endpoint
Assessment of incidence of serious adverse device effects (SADEs) and procedure-related serious adverse events (SAEs). Incidence of adverse device effects (ADEs) and procedure-related adverse events (AEs)
Time frame: at 6 weeks, 3 months, 6 months (ADEs and AEs only) and annually years 1-5
Secondary efficacy endpoint: HRQL all other timepoints
Percent reduction from baseline of GERD symptoms based on the GERD-HRQL score (questions 1-10)
Time frame: measured at baseline, 6 weeks, 3 months and follow-up years 1-5
Secondary efficacy endpoint: additional questions
Reduction from baseline of GERD symptoms based on the total GERD-HRQL score (questions 1-10) and individual symptom questions
Time frame: measured at baseline, 6 weeks, 3 months, 6 months and follow up years 1-5
Secondary efficacy endpoint: 24-hr pH monitoring
Reduction or normalisation from baseline of the total acid (pH\<4) exposure time on 24-hour pH monitoring
Time frame: measured at baseline, 6 months, 5 years and if therapy failure
Secondary efficacy endpoint: PPI usage
Reduction from baseline of the percentage of subjects with regular daily PPI usage
Time frame: measured at baseline, 6 weeks, 3 months, 6 months and follow up years 1-5
Secondary efficacy endpoint: Foregut
Reduction from baseline of individual foregut questionnaire scores focusing on regurgitation and additional information on dysphagia and odynophagia reported as AEs, or alternatively GERD-HRQL questions \>2 and/or \>3
Time frame: measured at baseline, 6 weeks, 3 months, 6 months and follow up years 1-5
Secondary efficacy endpoint: Endoscopy
Improvement in esophagitis on upper endoscopy
Time frame: measured at baseline, 6 months and if therapy failure
Secondary efficacy endpoint: device location
Location and function of the device evaluated by a simplified contrast swallow x-ray with overview pictures of device and LES position during swallowing
Time frame: measured at hospital stay, 6 weeks, 6 months, 5 years and if therapy failure
Secondary efficacy subgroup endpoint
Reduction or change comparison based on the following subgroups: age, gender, weight and result of baseline total GERD-HRQL score, comparing the following secondary endpoints: the total acid (pH\<4) exposure time on routine 24-hour pH monitoring at month 6 and the number and percentage of subjects having verified therapy failure
Time frame: per patient any point in the study triggered either by regular daily PPI usage or a GERD-HRQL score with less than 50% improvement compared to baseline, and having been verified as therapy failure via 24-hr pH monitoring and x-ray results
Exploratory endpoint: procedure complications
Assess any procedure-related complications
Time frame: during procedure
Exploratory endpoint: Procedure time
Assess time to perform the procedure
Time frame: during procedure
Exploratory endpoint: length of hospital stay
Assess length of the subject's hospital stay
Time frame: from date of admission to date of discharge, assessed up to 100 months
Plan to share: No
Ran from Dec 2016 to primary completion in Mar 2018, 15 months.
Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 15 months is below that.
Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Implantica CE Reflux Ltd.